2232923
Project Grant
Overview
Grant Description
SBIR Phase I: Filter Removal of Glass - A Better Way of Filtering Injectables - The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is an integrated, single needle filter which removes glass shards from injectable fluids.
Liquid pharmaceuticals and medications are often stored in glass ampoules. To gain access to these medications, each ampoule is manually broken at the neck by a healthcare provider. This can result in glass shards entering the medication that can cause patient hematomas and/or internal bleeding.
United States regulations currently mandate all ampoules must be filtered by healthcare providers prior to injection, which requires a multi-step filter process using multiple needles and needle exchanges. This project aims to develop a single, effective, inline filter that requires half the time of this current process, while improving safety for the patient and the healthcare worker by reducing the risks of needle stick injuries.
The commercial potential is to become the standard of care for the $3 billion global filter market and consumes over six billion disposable glass ampoules every year. This Small Business Innovation Research (SBIR) Phase I project is a novel, disposable, inline, mechanical filter with optimal porosity and density to remove glass ampoule shards.
The current practice of breaking ampoules at their neck to access medication results in shards that are currently manually filtered using a filter needle prior to administration into the patient. The filter needle must be removed and discarded, and a second sterile needle placed on the syringe for injection.
The company aims to develop a novel, all-in-one, integrated filter and needle system utilizing a single inner blunt needle with a novel filter located at the distal end versus the current proximal end where the luer loc is located. This solution will enable a single-step process for glass filtering and medication injection.
The scope of activities includes engineering and validation tests of leakage, pull force, dead volume, labeling and packaging, handling safety, repeatability/consistency, and accelerated aging of the company's proprietary design concepts. This project aims to provide an assembly suitable for human use that is manufacturable at scale in a cost-effective manner.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria. Subawards are not planned for this award.
Liquid pharmaceuticals and medications are often stored in glass ampoules. To gain access to these medications, each ampoule is manually broken at the neck by a healthcare provider. This can result in glass shards entering the medication that can cause patient hematomas and/or internal bleeding.
United States regulations currently mandate all ampoules must be filtered by healthcare providers prior to injection, which requires a multi-step filter process using multiple needles and needle exchanges. This project aims to develop a single, effective, inline filter that requires half the time of this current process, while improving safety for the patient and the healthcare worker by reducing the risks of needle stick injuries.
The commercial potential is to become the standard of care for the $3 billion global filter market and consumes over six billion disposable glass ampoules every year. This Small Business Innovation Research (SBIR) Phase I project is a novel, disposable, inline, mechanical filter with optimal porosity and density to remove glass ampoule shards.
The current practice of breaking ampoules at their neck to access medication results in shards that are currently manually filtered using a filter needle prior to administration into the patient. The filter needle must be removed and discarded, and a second sterile needle placed on the syringe for injection.
The company aims to develop a novel, all-in-one, integrated filter and needle system utilizing a single inner blunt needle with a novel filter located at the distal end versus the current proximal end where the luer loc is located. This solution will enable a single-step process for glass filtering and medication injection.
The scope of activities includes engineering and validation tests of leakage, pull force, dead volume, labeling and packaging, handling safety, repeatability/consistency, and accelerated aging of the company's proprietary design concepts. This project aims to provide an assembly suitable for human use that is manufacturable at scale in a cost-effective manner.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria. Subawards are not planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF22551
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Frederick,
Maryland
21704-9452
United States
Geographic Scope
Single Zip Code
Related Opportunity
22-551
Carrtech was awarded
Project Grant 2232923
worth $275,000
from National Science Foundation in September 2023 with work to be completed primarily in Frederick Maryland United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I:Filter Removal of Glass - A better way of filtering injectables
Abstract
The broader impact/commercial potential of this Small Business innovation Research (SBIR) Phase I project is an integrated, single needle filter which removes glass shards from injectable fluids.Liquid pharmaceuticals and medications are often stored in glass ampoules. To gain access to these medications, each ampoule is manually broken at the neck by a health care provider. This can result in glass shards entering the medication that can cause patient hematomas and/or internal bleeding. United States regulations currently mandate all ampoules must be filtered by health care providers prior to injection which requires a multi-step filter process using multiple needles and needle exchanges. This project aims to develop a single, effective, inline filter which that requires half the time of this current process, while improving safety for the patient and the healthcare worker by reducing the risks of needle stick injuries. The commercial potential is to become the standard of care for the $3 billion global filter market and consumes over six billion disposable glass ampoules every year._x000D_ _x000D_ This Small Business Innovation research (SBIR) Phase I project is a novel, disposable, inline, mechanical filter with optimal porosity and density to remove glass ampoule shards. The current practice of breaking ampules at their neck to access medication results in shards that are currently manually filtered using a filter needle prior to administration into the patient. The filter needle must be removed and discarded, and a second sterile needle placed on the syringe for injection. The company aims to develop a novel, all-in-one, integrated filter and needle system utilizing a single inner blunt needle with a novel filter located at the distal end versus the current proximal end where the Luer loc is located.This solution will enable a single step process for glass filtering and medication injection. The scope of activities includes engineering and validation tests of leakage, pull force, dead volume, labeling and packaging, handling safety, repeatability/consistency, and accelerated aging of the company’s proprietary design concepts. This project aims to provide an assembly suitable for human use that is manufacturable at scale in a cost-effective manner._x000D_ _x000D_ This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
MD
Solicitation Number
NSF 22-551
Status
(Complete)
Last Modified 9/5/23
Period of Performance
9/1/23
Start Date
8/31/24
End Date
Funding Split
$275.0K
Federal Obligation
$0.0
Non-Federal Obligation
$275.0K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2232923
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
MMJYFTXCP4M8
Awardee CAGE
6QXG9
Performance District
MD-06
Senators
Benjamin Cardin
Chris Van Hollen
Chris Van Hollen
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
Research and Related Activities, National Science Foundation (049-0100) | General science and basic research | Grants, subsidies, and contributions (41.0) | $275,000 | 100% |
Modified: 9/5/23